Analyst consensus rating
Maze Therapeutics Analyst Rating: Strong Buy
MAZE is rated Strong Buy by 11 analysts with a $62.55 target. As of 2026-08-25.
Direct answer
Maze Therapeutics's consensus rating is Strong Buy.
11 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $62.55.
Forecast evidence checked August 25, 2026.
Get free Maze Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $30.50
- Average price target
- $62.55
- High price target
- $110.00
- Low price target
- $46.00
- Low target gap
- +50.8%
- Target upside
- +105.1%
- High target gap
- +260.7%
- Target range width
- 209.8%
- Consensus rating
- Strong Buy
- Analysts
- 11
- Evidence date
- August 25, 2026
- Valid through
- September 1, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Maze Therapeutics?
Maze Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $62.55.
How far are Maze Therapeutics's low and high targets from the recorded price?
The low target implies +50.8%, while the high target implies +260.7%.
How many analysts are included in Maze Therapeutics's consensus?
The verified consensus includes 11 analysts.
How is Maze Therapeutics's target upside or downside calculated?
The average target of $62.55 is divided by the recorded price of $30.50, then one is subtracted to produce +105.1%. This does not guarantee a future return.
When was Maze Therapeutics's analyst forecast verified?
The data was verified on 2026-08-25. The dataset is valid through 2026-09-01.